RESUMEN
Depression is a frequent diagnosis for people with dementia, with between 25% and 42% of such patients receiving antidepressants. The diagnosis can be challenging to make, and this patient group is more vulnerable to side effects of commonly used medications. This article outlines the diagnostic considerations and therapeutic approaches for managing depression in people with dementia.
Asunto(s)
Demencia/psicología , Trastorno Depresivo/psicología , Anciano , Antiinflamatorios no Esteroideos/efectos adversos , Antidepresivos/uso terapéutico , Trastorno Depresivo/diagnóstico , Trastorno Depresivo/terapia , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Terapia por Ejercicio , Hemorragia Gastrointestinal/inducido químicamente , Humanos , Apoyo Social , Accidente Cerebrovascular/psicologíaRESUMEN
Memantine is the first agent licensed for the treatment of moderate to severe Alzheimer's disease. It is an N-methyl D-aspartate (NMDA) receptor antagonist which reduces glutamatergic excitotoxicity. Benefits are seen in cognitive, functional and global measures in both outpatients and nursing home residents. Prospective health economic benefits have been reported.